[Clinical pharacology of the new antihypertensive drugs: renin-angiotensin system antagonists, recent vasodilators and dopaminergic agonists].
D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents / Q000494:pharmacology*; D018492:Dopamine Antagonists; D006801:Humans; D007741:Labetalol / Q000494:pharmacology; D008914:Minoxidil / Q000494:pharmacology; D009543:Nifedipine / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D012504:Saralasin / Q000494:pharmacology; D013764:Tetrahydronaphthalenes / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology*; D000092502:Renin Inhibitors
D000804:Angiotensin II; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D018492:Dopamine Antagonists; D007741:Labetalol; D008914:Minoxidil; D009543:Nifedipine; D011224:Prazosin; D012504:Saralasin; D013764:Tetrahydronaphthalenes; D014665:Vasodilator Agents; D000092502:Renin Inhibitors
Pharmacologie clinique des nouveaux antihypertenseurs: antagonistes du système rénine-angiotensine, vasodilatateurs récents et agonistes dopaminergiques.